Selincro is a new drug used to reduce alcohol consumption in adults with alcohol dependence.
|Selincro (Brand)||Selincro||Brand||18mg||14 Tablets||$110.00|
Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification. Selincro should only be prescribed in conjunction with continuous psycho social support focused on treatment adherence and reducing alcohol consumption. Selincro should be initiated only in patients who continue to have a high DRL two weeks after initial assessment.
Based on in vitro studies, no clinically relevant interactions between nalmefene, or its metabolites, and concomitantly administered medicinal products metabolised by the most common CYP450 and UGT enzymes or membrane transporters are anticipated. Coadministration with medicinal products that are potent inhibitors of the UGT2B7 enzyme (for example, diclofenac, fluconazole, medroxyprogesterone acetate, meclofenamic acid) may significantly increase the exposure to nalmefene. This is unlikely to present a problem with occasional use, but if long-term concurrent treatment with a potent UGT2B7 inhibitor is initiated, a potential for an increase in nalmefene exposure cannot be excluded. Conversely, concomitant administration with a UGT inducer (for example, dexamethasone, phenobarbital, rifampicin, omeprazole) may potentially lead to subtherapeutic nalmefene plasma concentrations. If Selincro is taken concomitantly with opioid agonists (for example, certain types of cough and cold medicinal products, certain antidiarrhoeal medicinal products, and opioid analgesics), the patient may not benefit from the opioid agonist. There is no clinically relevant pharmacokinetic drug-drug interaction between nalmefene and alcohol. There seems to be a small impairment in cognitive and sychomotor performance after administration of nalmefene. However, the effect of nalmefene and alcohol in combination did not exceed the sum of the effects of each substance when taken alone. Simultaneous intake of alcohol and Selincro does not prevent the intoxicating effects of alcohol.
How does nalmefene work? Nalmefene works by blocking opiate receptors in the brain, reducing cravings in alcohol-dependent drinkers and consequently reducing alcohol consumption. What is alcohol dependence? Alcohol dependence is also called alcoholism. A central characteristic of alcohol dependence is the often overpowering desire to consume alcohol. Patients experience difficulties in controlling the consumption of alcohol and continue drinking alcohol despite harmful consequences. Alcoholism is a long-term (chronic) disease. It’s not a weakness or a lack of willpower. Alcohol dependence increases the risk of developing high blood pressure, stroke, heart disease and liver disease. Alcohol dependence can also cause anxiety, depression and suicidal feelings, and is associated with increased criminal activity and domestic violence. In the United Kingdom, it is estimated that 9% of men and 4% of women are affected by alcohol dependence.
Medicare is the health insurance program for US citizens. You are eligible for coverage if you are over the age of 65 or if you have qualifying disabilities and are under the age of 65.